Literature DB >> 6785126

The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine.

B J Montagnon, B Fanget, A J Nicolas.   

Abstract

As the increasing shortage of monkeys is a reality, the application of an alternative cell substrate for large-scale production of Killed Poliomyelitis Vaccine (KPV) was studied. Through progress of scientific knowledge the non-tumorigenic VERO cell line was considered to be a suitable alternative cell substrate for this purpose. The Master-Cell-Bank and Working-Cell-Banks prepared by us are giving a practically inexhaustible cell source. Using micro-carrier culture, weekly more than 400 billions of cells at a concentration of 10(6) cells per ml could be obtained for virus inoculation. The virus yield per cell was at least as high as for primary monkey kidney cells. Processing of virus harvests could be performed according to the methods used at the production on primary monkey kidney cells. From a technological view-point large-scale production of KPV on VERO cells appears to be possible economically. More research on the safety control might be necessary.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6785126

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  21 in total

1.  Evaluation of the serum-free medium MDSS2 for the production of poliovirus on vero cells in bioreactors.

Authors:  O W Merten; R Wu; E Couvé; R Crainic
Journal:  Cytotechnology       Date:  1997-11       Impact factor: 2.058

2.  Introduction to animal cell culture technology-past, present and future.

Authors:  O-W Merten
Journal:  Cytotechnology       Date:  2006-08-03       Impact factor: 2.058

3.  The new medium MDSS2N, free of any animal protein supports cell growth and production of various viruses.

Authors:  O W Merten; H Kallel; J C Manuguerra; M Tardy-Panit; R Crainic; F Delpeyroux; S Van der Werf; P Perrin
Journal:  Cytotechnology       Date:  1999-07       Impact factor: 2.058

4.  Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs.

Authors:  I V Alymova; S Kodihalli; E A Govorkova; B Fanget; C Gerdil; R G Webster
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Authors:  Y Whang; M Silberklang; A Morgan; S Munshi; A B Lenny; R W Ellis; E Kieff
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

6.  Clinical trial of hepatitis B vaccine in a simplified immunization programme.

Authors:  P Coursaget; B Yvonnet; M Sarr; P Vincelot; E Tortey; S Mboup; J P Chiron; I Diop-Mar
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

7.  High titre Hog Cholera virus production on Cytodex 3 microcarrier cultures.

Authors:  A Caij; A De Smet; N Dubois; F Koenen
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

8.  Activation of metastatic potential in African green monkey kidney cell lines by prolonged in vitro culture.

Authors:  G Contreras; R Bather; J Furesz; B C Becker
Journal:  In Vitro Cell Dev Biol       Date:  1985-11

9.  Reverse Genetics Approach for Developing Rotavirus Vaccine Candidates Carrying VP4 and VP7 Genes Cloned from Clinical Isolates of Human Rotavirus.

Authors:  Yuta Kanai; Misa Onishi; Takahiro Kawagishi; Pimfhun Pannacha; Jeffery A Nurdin; Ryotaro Nouda; Moeko Yamasaki; Tina Lusiany; Pattara Khamrin; Shoko Okitsu; Satoshi Hayakawa; Hirotaka Ebina; Hiroshi Ushijima; Takeshi Kobayashi
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

10.  Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics.

Authors:  Hiroichi Ozaki; Elena A Govorkova; Chenghong Li; Xiaoping Xiong; Robert G Webster; Richard J Webby
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.